Precigen Gets FDA Priority Review of Recurrent Respiratory Papillomatosis Treatment
Precigen on Tuesday said a green light would make PRGN-2012 the only FDA-approved therapeutic for the treatment of adults with the disorder, which is a lifelong neoplastic disease of the upper and ...
Precigen’s BLA for PRGN-2012 in papillomatosis granted priority review by FDA
Precigen (PGEN) announced the FDA has accepted the company’s biologics license application, or BLA, for PRGN-2012, an investigational ...
震撼！癌症疫苗界“神仙打架”，攻克胰腺癌、胆道癌、胃癌、食管 ...
EVX-01是一种基于肽的个性化癌症疫苗，旨在用于多种晚期实体癌的一线治疗。2024年欧洲肿瘤内科学会（ESMO）大会上公布了该试验的积极数据。结果显示：16名患者中有 ...